A review of hepatitis B management in pre- and post-liver transplant recipients

Open Immunology Journal

Volumn 3, Issue 1, 2010, Pages 27-35

  Mukherjee, Sandeep ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Decompensated cirrhosis; Hepatitis B; Hepatitis B immune globulins; Liver transplantation; Nucleos(t)ide; Prophylaxis

Indexed keywords

ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; ENTECAVIR; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; NUCLEOSIDE ANALOG; PEGINTERFERON ALPHA2A; TELBIVUDINE; TENOFOVIR;

ANTIVIRAL RESISTANCE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; CREATININE BLOOD LEVEL; DISEASE EXACERBATION; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; GRAFT SURVIVAL; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; KIDNEY DISEASE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER TRANSPLANTATION; ORGAN DONOR; PRIORITY JOURNAL; PROGNOSIS; RECURRENT INFECTION; REVIEW; SEROCONVERSION; SIDE EFFECT; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VIRUS LOAD;

EID: 78249267264     PISSN: None     EISSN: 18742262     Source Type: Journal    
DOI: 10.2174/1874226201003010027     Document Type: Review

References (72)

1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment and current and emerging prevention and control measures. J Viral Hepat 2004; 11: 97-107.
2. Kim WR. Epidemiology of hepatitis B in the United States. Hepatology 2009; 49: S28-34.
3. Kim WR, Terrault NA, Pedersen RA, et al. Trends in waitlist registration for liver transplantation for viral hepatitis in the US. Gastroenterology 2009; 137: 1680-6.
4. Pungapong S, Kim WR, Poterucha JJ. Natural history of hepatitis B virus infection: an update for clinicians. Mayo Clin Proc 2007; 82: 967-75.
5. Hoofnagle JH. Reactivation of hepatitis B. Hepatology 2009; 49 (5 Suppl): S156-65.
6. Loomba R, Rowley A, Wesley R, et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 2008; 148: 519-28.
7. Palmore TN, Shah NL, Loomba R, et al. Reactivation of hepatitis B with reappearance of hepatitis B surface antigen after chemotherapy and immune suppression. Clin Gastroenterol Hepatol 2009; 7: 1130-7.
8. European Association for the Study of Liver. EASL Clinical practice guidelines: Management of chronic hepatitis B. J Hepatol 2009; 50: 227-42.
9. Terrault NA. Benefits and risks of combination therapy for hepatitis B. Hepatology 2009; 49 (5 Suppl): S122-8.
10. Sorrell MF, Belongia EA, Costa J, et al. National Institutes of Health Consensus Development Conference Statement: management of hepatitis B. Ann Intern Med 2009; 150: 104-10.
11. Keeffe EB, Dieterich DT, Han SH, et al. Treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol 2008; 6: 1315-41.
12. Papatheodoridis GV, Cholongitas E, Archimandritis AJ, Burroughs AK. Current management of hepatitis B virus infection before and after liver transplantation. Liver Int 2009; 29: 1294-305.
13. Dienstag JL. Hepatitis B virus infection. N Engl J Med 2008; 359: 1486-500.
14. Perrillo RP, Wright T, Rakela J, et al. Lamivudine North American Transplant Group. A multicenter United States - Canadian trial to assess lamivudine monotherapy before and after liver transplantation. Hepatology 2001; 33: 424-32.
15. Fontana RJ, Hann HW, Perrillo RP, et al. Determinants of early mortality on patients with decompensated chronic hepatitis B treated with antiviral therapy. Gastroenterology 2002; 123: 719-27.
16. Grellier L, Multimer D, Ahmed M, et al. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 1996; 348: 1212-15.
17. Perillo R, Rakela J, Dienstag J, et al. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Lamivudine Transplant Group. Hepatology 1999; 29: 1581-86.
18. Schiff ER, Lai CL, Hadziyannis S, et al. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre-and post-liver transplantation patients. Hepatology 2003; 38: 1419-27.
19. Schiff E, Lai CL, Hadziyannis S, et al. Adefovir dipivoxil for waitlisted and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl 2007; 13: 349-60.
20. Villeneuve JP, Durantel D, Durantel S, et al. Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. J Hepatol 2003; 39: 1085-9.
21. Villet S, Pichoud C, Villeneuve JP, Trépo C, Zoulim F. Selection of a multiple -resistant hepatitis B virus strain in a liver transplanted patient. Gastroenterology 2006; 131: 1253-61.
22. Ratziu V, Thibault V, Benhamou Y, Poynard T. Successful rescue therapy with tenofovir in a patient with hepatic decompensation and adefovir resistant HBV mutant. Comp Hepatol 2006; 5: 1.
23. Choe WH, Kwon SY, Kim BK, et al. Tenofovir plus lamivudine as rescue therapy for adefovir-resistant chronic hepatitis B in hepatitis B e antigen-positive patients. Liver Int 2008; 28: 814-20.
24. Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBe Ag-positive chronic hepatitis B. N Engl J Med 2006; 354: 1001-10.
25. Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBe Ag-negative chronic hepatitis B. N Engl J Med 2006; 354: 1011-20.
26. Colonno RJ, Rose R, Baldick CJ, et al. Entecavir resistance is rare in nucleoside naïve patients with hepatitis B. Hepatology 2006; 44: 1656-65.
27. Sherman M, Yurdaydin C, Sollano J, et al. Entecavir for treatment of lamivudine-refractory HBeAg-positive chronic hepatitis B. Gastroenterology 2006; 130: 2039-49.
28. Tenney DJ, Rose RE, Baldick CJ, et al. Two year assessment of entecavir resistance in lamivudine-refractory hepatitis B patients reveals different clinical outcomes depending on the resistance substitution present. Antimicrob Agents Chemother 2007; 51: 902-11.
29. Villet S, Ollivet A, Pichoud C, et al. Stepwise process for the development of enetecavir resistanace in a chronic hepatitis B virusinfected patients. J Hepatol 2007; 46: 531-8.
30. Marcellin P, Jenny Heathcoate E, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008; 359: 2442-55.
31. Lai CL, Leung N, Teo EK, et al. A 1 year trial of telbivudine, lamivudine and the combination in patients with hepatitis B e antigen positive chronic hepatitis B. Gastroenterology 2005; 129: 528-36.
32. Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007; 357: 2576-88.
33. Dodson SF, Issa S, Araya V, et al. Infectivity of hepatic allografts with antibodies to hepatitis B virus. Transplantation 1997; 64: 1582-4.
34. Ikegami T, Taketomi A, Ohta R, et al. The risks of HBV infection after liver transplantation from HBc antibody positive donor to the HBs antibody recipient. Hepatogastroenterology 2008; 55: 2162-5.
35. Dodson SF, Issa S, Araya V, et al. Antibodies to hepatitis B surface antigen prevents reactivation in recipients of liver grafts from anti-Hb core anti-HB c positive donors. Gut 2002; 50: 95-9.
36. Holt D, Thomas R, Van Thiel D, Brems JJ. Use of hepatitis B core antibody-positive donors in orthotopic liver transplantation. Arch Surg 2002; 137: 572-5.
37. Perrillo R. Hepatitis B virus prevention strategies for antibody to hepatitis B core antigen positive liver donation: a survey of North American, European and Asian-Pacific transplant programs. Liver Transpl 2009; 15: 223-32.
38. Davies SE, Portmann BC, O'Grady JG, et al. Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis. Hepatology 1991; 13: 150-7.
39. Todo S, Demetris AJ, Van Thiel D, Teperman L, Fung JJ, Starzl TE. Orthotopic liver transplantation for hepatitis B-virus related liver disease. Hepatology 1991; 13: 619-26.
40. O'Grady JG, Smith HM, Davies SE, et al. Hepatitis B virus infection after orthotopic liver transplantation. Serological and clinical implications. J Hepatol 1992; 14: 104-11.
41. Muller R, Gubernatis G, Farle M, et al. Liver transplantation in hepatitis B surface antigen carriers. Prevention of hepatitis B virus recurrence by passive immunization. J Hepatol 1991; 13: 90-96.
42. Samuel D, Muller R, Alexander G, et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993; 329: 1842-47.
43. Mutimer D, Pillay D, Dragon E, et al. High pre-treatment serum hepatitis B virus titre predicts failure of lamivudine prophylaxis and graft re-infection after liver transplantation. J Hepatol 1999; 30: 715-21.
44. Rosenau J, Bahr MJ, Tillmann HL, et al. Lamivudine and low-dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation: possible role of mutations in the YMDD motif prior to liver transplantation as a risk factor for reinfection. J Hepatol 2001; 34: 895-902.
45. Marzano A, Salizzoni M, Debernadi-Vernon W, et al. Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. J Hepatol 2001; 34: 903-10.
46. Seehofer D, Rayes N, Naumann U, et al. Preoperative antiviral treatment and postoperative prophylaxis in HBV-DNA positive patients undergoing liver transplantation. Transplantation 2001; 72: 1381-85.
47. Markowitz JS, Martin P, Conrad AJ, et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 1998; 28: 585-9.
48. Han SH, Ofman J, Holt C, et al. An efficacy and cost-effectiveness analysisof combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy. Liver Transpl 2000; 6: 741-8.
49. Rosenau J, Bahr MJ, Tilmann HL, et al. Lamivudine and low-dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation: possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection. J Hepatol 2001; 34: 895-902.
50. Steinmuller T, Seehofer D, Rayes N, et al. Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease. Hepatology 2002; 35: 1528-35.
51. Dan Y, Wai C, Yeoh K, Lim S. Prophylactic strategies for hepatitis B patients undergoing liver transplant: a cost-effectiveness analysis. Liver Transpl 2006; 12: 736-46.
52. Anderson RD, Chinnakotla S, Guo L, Perrillo RP, Klintmalm GB, Davis GL. Intramuscular hepatitis B immunoglobulin and nucleosides for prevention of recurrent hepatitis B following liver transplantation: comparison with other HBIG regimens. Clin Transplant 2007; 21: 510-7.
53. Gane EJ, Angus PW, Strasser S, et al. Lamivudine plus low dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation. Gastroenterology 2007; 132: 931-7.
54. Angus PW, Patterson SJ, Strasser SI, McCaughan GW, Gane E. A randomized study of adefovir dipoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis. Hepatology 2008; 48: 1460-6.
55. Angus PW, McCaughan GW, Gane EJ, Crawford DH, Harley H. Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B. Liver Transpl 2000; 6: 429-33.
56. Ferreti G, Merli M, Ginanni CS, et al. Low-dose hepatitis B immune globulin and lamivudine for long-term prophylaxis of hepatitis B recurrence after liver transplantation. Transplant Proc 2004; 3: 535-8.
57. Karademir S, Astacioglu H, Akarsu M, et al. Prophylactic use of lowdose, on-demand intramuscular hepatitis B immune globulin and lamivudine after liver transplant. Transplant Proc 2006; 38: 579-83.
58. Zheng S, Chen Y, Liang T, et al. Prevention of hepatitis B recurrence after liver transplantation using lamivudine or lamivudine combined with hepatitis B immune globulin. Liver Transpl 2006; 12: 253-8.
59. Rao W, Wu X, Xiu D. Lamivudine or lamivudine combined with hepatitis B immunoglobulin in prophylaxis of hepatitis B recurrence after liver transplantation: a meta-analysis. Transpl Int 2009; 22: 387-94.
60. Saab S, Ham MY, Stone MA, Holt C, Tong M. Decision analysis model for hepatitis B prophylaxis one year after liver transplantation. Liver Transpl 2009; 15: 413-20.
61. Nath DS, Kalis A, Nelson S, Payne WD, Lake JR, Humar A. Hepatitis B prophylaxis post-liver transplant without maintenance hepatitis B immunoglobulin. Clin Transplant 2006; 20: 206-10.
62. Angus PW, Patterson SJ, Strasser SI, McCaughan GW, Gane EJ. A randomized study of adefovir dipvoxil in place of HBIG in combination with lamivudine as post-liver transplant HBV prophylaxis. Hepatology 2008; 48: 1460-8.
63. Yamamoto M, Little G, Imagawa DK. Hepatitis B immunoglobulin in preventing reinfection following liver transplantation. Expert Rev Anti Infect Ther 2009; 7: 321-8.
64. Chang TT, Chao Y, Gorbakov VV, et al. Results of up to 2 years of entecavir versus lamivudine therapy in nucleoside-naïve HBeAgpositive patients with chronic hepatitis. J Viral Hepat 2009; 16: 784-9.
65. Han S, Chang T, Chao Y, et al. Four year entecavir treatment in nucleoside naïve HbsAg+ patients:results from studies ETV-022 and-091. Hepatology 2007; 46: 654.
66. Fung SK, Chae HB, Fontana RJ, et al. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol 2006; 44: 283-90.
67. Limquiaco JL, Wong J, Wong VW, et al. Lamivudine monoprophylaxis and adefovir salvage for liver transplantation in chronic hepatitis B: a seven year follow-up study. J Med Virol 2009; 81: 224-9.
68. Camci C, Gurakar A, Rose J, et al. Liver transplantation for hepatitis B in the United States. Transplant Proc 2005; 37: 4350-3.
69. Beckebaum S, Sotiropoulos GC, Klein CG, et al. Predictive factors of outcome in patients transplanted for hepatitis B. Transplantation 2009; 87: 872-81.
70. Kim WR, Poterucha JJ, Kremers WK, Ishitani MB, Dickson ER. Outcome of liver transplantation for hepatitis B in the United States. Liver Transpl 2004; 10: 968-74.
71. Roche B, Samuel D. Liver transplantation in viral hepatitis: prevention of recurrence. Best Pract Res Clin Gastroenterol 2009; 22: 1153-69.
72. Patterson SJ, Angus PW. Post-liver transplant hepatitis B prophylaxis: the role of oral nucleos(t)ide analogues. Curr Opin Organ Transplant 2009; 14: 225-30.